Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B17 | O75795 | 2/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 11/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 11/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | STS | P08842 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7242871 | 0.80 | EBP (0.41) | UGT2B17 | |
| SCHEMBL27322693 | 0.74 | MEN1 (0.38) | UGT2B17LTB4RLTB4R2MAPTALDH1A1 | |
| SCHEMBL7245450 | 0.74 | NPC1 (0.36) | UGT2B17LTB4RLTB4R2MAPT | |
| SCHEMBL31558350 | 0.72 | LTB4R (0.53) | LTB4RLTB4R2GBA1 | |
| SCHEMBL7241734 | 0.70 | HTR6 (0.46) | LTB4RLTB4R2 | |
| Hydrochloric Acid SCHEMBL10446805 | 0.70 | EBP (0.44) | UGT2B17MAPT | |
| SCHEMBL7249674 | 0.70 | BLM (0.41) | LTB4RLTB4R2GBA1ALDH1A1 | |
| SCHEMBL7251512 | 0.69 | ACHE (0.51) | — | |
| SCHEMBL1508636 | 0.69 | UGT2B17 (0.82) | UGT2B17 | |
| SCHEMBL7250487 | 0.69 | CYP19A1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | GOLDSTEIN STEVEN WAYNE (US) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191279-A1 | Urea derivatives useful as anticancer agents | CCNA1, CCNE1, CCND1 | UGT2B17 552/4885LTB4R 3845/4885LTB4R2 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.